Busch Gabi, Seitz Isabell, Steppich Birgit, Hess Sibylle, Eckl Robert, Schömig Albert, Ott Ilka
Deutsches Herzzentrum und Medizinische Klinik der Technischen Universität München, Germany.
Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):461-6. doi: 10.1161/01.ATV.0000151279.35780.2d. Epub 2004 Nov 18.
In acute myocardial infarction (AMI), proinflammatory plasma C-reactive protein values are strongly associated with postinfarction morbidity and mortality. So far, the cause of these inflammatory changes is not well understood. Therefore, we sought to investigate the relationship between the activation of coagulation and subsequent systemic inflammatory changes in AMI.
Factor Xa (FXa) bound to tissue factor pathway inhibitor and prothrombin fragments F1+2 (F1+2) were used as a measure for activated coagulation. To assess systemic inflammatory changes, plasma interleukin (IL)-6 and IL-8 concentrations were analyzed by immunoassay. Blood samples were taken from 21 patients with AMI and 20 patients with stable angina pectoris. In AMI, tissue factor pathway inhibitor FXa but not F1+2 plasma levels were associated with circulating IL-8 (P=0.01). In vitro experiments revealed that FXa stimulated IL-8 and monocyte chemoattractant protein-1 release and RNA expression in endothelial cells and mononuclear leukocytes by activation of protease-activated receptor-1.
Our data suggest that coagulation FXa may contribute to proinflammatory changes in AMI by stimulation of IL-8 release. Therapeutic inhibition of the proinflammatory effects of FXa may improve the clinical course in AMI. This study investigates the relationship between the activation of coagulation and systemic inflammatory changes in acute myocardial infarction. Tissue factor pathway inhibitor factor Xa but not F1+2 plasma levels were associated with circulating interleukin-8. In vitro factor Xa stimulated interleukin-8 and monocyte chemoattractant protein-1 release and RNA expression by activation of protease-activated receptor 1 as an underlying mechanism.
在急性心肌梗死(AMI)中,促炎血浆C反应蛋白值与梗死后发病率和死亡率密切相关。到目前为止,这些炎症变化的原因尚不清楚。因此,我们试图研究AMI中凝血激活与随后全身炎症变化之间的关系。
结合组织因子途径抑制剂的因子Xa(FXa)和凝血酶原片段F1+2(F1+2)被用作凝血激活的指标。为了评估全身炎症变化,通过免疫测定分析血浆白细胞介素(IL)-6和IL-8浓度。从21例AMI患者和20例稳定型心绞痛患者采集血样。在AMI中,组织因子途径抑制剂FXa而非F1+2血浆水平与循环IL-8相关(P=0.01)。体外实验表明,FXa通过激活蛋白酶激活受体-1刺激内皮细胞和单核白细胞释放IL-8和单核细胞趋化蛋白-1并促进其RNA表达。
我们的数据表明,凝血FXa可能通过刺激IL-8释放导致AMI中的促炎变化。对FXa促炎作用的治疗性抑制可能改善AMI的临床病程。本研究调查了急性心肌梗死中凝血激活与全身炎症变化之间的关系。组织因子途径抑制剂因子Xa而非F1+2血浆水平与循环白细胞介素-8相关。体外实验中,因子Xa通过激活蛋白酶激活受体1刺激白细胞介素-8和单核细胞趋化蛋白-1释放及RNA表达,这是潜在机制。